5月13日 - ** 药物开发商CytokineticsCYTK.O股价盘前上涨5.2%至33.80美元
** 公司称,在一项后期研究中,与标准疗法相比,实验性心脏病药物aficamten有助于显著提高患者的运动能力 (link)
** 加拿大皇家银行资本市场(RBC Capital Markets)预计,到 2034 年,aficamten 在这一适应症上的销售机会将达到 9 亿美元,而其总销售机会为 39 亿美元。
** 美国食品和药物管理局(FDA)将aficamten上市申请的审查日期推迟到12月后,CYTK的股价在5月份至今已暴跌25% (link)
** 总体而言,该公司股价在今年下跌了约32%。
(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.